[미국특허]
Absorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-001/02
A61K-035/14
C12N-007/06
C12M-001/00
C07K-001/00
출원번호
US-0016323
(2001-12-10)
발명자
/ 주소
Hei, Derek J.
Clarke, Michael S.
출원인 / 주소
Cerus Corporation
대리인 / 주소
Morrison &
인용정보
피인용 횟수 :
12인용 특허 :
71
초록▼
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent partic
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 1 μm to about 200 μm. The matrix can be fibrous, and the particles can have a surface area greater than 750 m2/g and a pore diameter between about 25 and 800 Å. The device can be used to adsorb and remove a pathogen-inactivating compound that is a nucleic acid-binding compound such as psoralen, an acridine derivative or a dye from a biological composition such as a blood product.
대표청구항▼
1. A pathogen-inactivating compound adsorption system for reducing the concentration of a low molecular weight pathogen-inactivating compound in a biological composition, wherein the pathogen-inactivating compound adsorption system comprises a housing compatible with the biological composition and c
1. A pathogen-inactivating compound adsorption system for reducing the concentration of a low molecular weight pathogen-inactivating compound in a biological composition, wherein the pathogen-inactivating compound adsorption system comprises a housing compatible with the biological composition and containing an adsorption medium comprising adsorbent particles having a network pore structure immobilized within a sintered matrix formed from polymeric particulate material, wherein the diameter of the adsorbent particles ranges from about 1 μm to about 200 μm, wherein the adsorbent particles have an affinity for said pathogen-inactivating compound, wherein the system is configured to remove said pathogen-inactivating compound from said biological composition in a flow process, wherein the system is configured so that the biological composition treated with the system maintains sufficient biological activity so that said biological composition is suitable for infusion within a human.2. A system according to claim 1, wherein the diameter of the adsorbent particles is between about 50 and 150 μm.3. A system according to claim 1, wherein the particle containing matrix is at least 3 mm thick.4. A system according to claim 1, wherein the adsorbent particles comprise adsorbent resin particles have a surface area greater than about 750 m2/g, and the porous adsorbent particles are between 30 and 70 percent of the weight of the adsorption medium.5. A system according to claim 1, wherein the adsorbent particles comprise adsorbent resin particles having a surface area greater than about 750 m2/g.6. A system according to claim 5, wherein the adsorbent resin particles are polyaromatic.7. A system according to claim 6, wherein said adsorbent resin particles have a pore diameter between about 25 and 800 Å.8. A system according to claim 7, wherein said adsorbent resin particles have a pore diameter between about 25 and 150 Å.9. A system according to claim 8, wherein said adsorbent resin particles have a pore diameter between about 25 and 50 Å.10. A system according to claim 5, wherein the adsorbent resin particles do not require prewetting before use.11. A system according to claim 5, wherein the adsorbent resin particles are hypercrosslinked.12. A system according to claim 1 or claim 5, wherein the pathogen inactivating compound comprises a nucleic acid-binding compound.13. A system according to claim 12, wherein the nucleic acid-binding compound comprises a psoralen.14. A system according to claim 12, wherein the nucleic acid-binding compound comprises an acridine derivative.15. A system according to claim 12, wherein the nucleic acid-binding compound comprises a dye.16. A system according to claim 12, wherein the adsorbent particles have an affinity for a nucleic acid-binding compound having an electrophilic group capable of reacting with a nucleophilic group of a quencher that quenches undesired side reactions of the pathogen-inactivating compound.17. A system according to claim 16, wherein the adsorbent particles additionally have an affinity for said quencher.18. A system according to claim 12, wherein the adsorbent particles additionally have an affinity for a degradation product of said nucleic acid-binding compound.19. A system according to claim 1, wherein the adsorbent particles have an internal surface area between about 300 and 1100 m2/g.20. A system according to claim 1 or claim 5 wherein the sintered matrix comprises a polyolefin.21. A system according to claim 20 wherein the polyolefin comprises polyethylene.22. A system according to claim 21 wherein the polyethylene comprises an ultra high molecular weight polyethylene.23. A system according to claim 1 wherein the adsorbent particles comprise activated carbon.24. A system according to claim 23 wherein the activated carbon has a surface area greater than 950 m 2/g.25. A system according to claim 24 wherein the activated carbon has a surface area greater than 1200 m2/g.26. A system according to claim 25 wherein the activated carbon has a surface area of about 2000 m2/g.27. A system according to claim 23 wherein the activated carbon is formed by steam activation of coconut shells.28. A system according to claim 5 wherein said adsorbent particles comprise nonionic macroporous and macroreticular resin particles having macropores and micropores.29. A method for reducing the concentration of a low molecular weight compound comprising a pathogen-inactivating compound in a biological composition, said method comprising treating the biological composition with a system of claim 1 or claim 5, to bind the low molecular weight compound to the adsorbent particles and thereby reduce the concentration of the low molecular weight compound in the biological composition, wherein the biological composition treated with the system maintains sufficient biological activity so that said biological composition is suitable for infusion within a human.30. A method for reducing the concentration of a low molecular weight compound comprising a nucleic acid-binding compound in a biological composition, said method comprising treating the biological composition with a system of claim 12 to bind the low molecular weight compound to the adsorbent particles and thereby reduce the concentration of the low molecular weight compound in the biological composition, wherein the biological composition treated with the system maintains sufficient biological activity so that said biological composition is suitable for infusion within a human.31. A method according to claim 30 wherein the nucleic acid-binding compound comprises an acridine derivative.32. A method according to claim 31, wherein the acridine derivative comprises N-(9-acridinyl)-β-alanine.33. A method according to claim 30, wherein the nucleic acid-binding compound comprises a dye.34. A method according to claim 33, wherein the dye comprises methylene blue.35. A method for reducing the concentration of a low molecular weight compound comprising a psoralen nucleic acid-binding compound in a biological composition, said method comprising treating the biological composition with a system of claim 12 to bind the low molecular weight compound to the adsorbent particles and thereby reduce the concentration of the low molecular weight compound in the biological composition, wherein the biological composition treated with the system maintains sufficient biological activity so that said biological composition is suitable for infusion within a human.36. A method according to claim 35, wherein no more than about ten percent of an amount of said psoralen nucleic acid-binding compound originally added to said biological composition remains as free psoralen in said biological composition.37. A method according to claim 35, wherein said psoralen nucleic acid-binding compound is selected from the group consisting of 4′-(4-amino-2-oxa)butyl-4,5′,8-trimethyl psoralen, 8-methoxypsoralen, halogenated psoralens, isopsoralens and psoralens linked to quaternary amines, 5′-bromomethyl-4,4′,8-trimethylpsoralen, 4′-bromomethyl-4,5′,8-trimethylpsoralen, 4′-(4-amino-2-aza)butyl-4,5′,8-trimethylpsoralen, 4′-(2-aminoethyl)-4,5′,8-trimethylpsoralen, 4′-(5-amino-2-oxa)pentyl-4,5′,8-trimethylpsoralen, 4′-(5-amino-2-aza)pentyl- 4,5′,8-trimethylpsoralen, 4′-(6-amino-2-aza)hexyl-4,5′,8-trimethylpsoralen, 4′-(7-amino-4,5′,8-trimethylpsoralen, 4′-(12-amino-8-aza-2,5-dioxa)dodecyl-4,5′,8-trimethylpsoralen, 4′-(13-amino-2-aza-6,11-dioxa)tridecyl-4,5′,8-trimethylpsoralen, 4′-(7-amino-2-aza)hep 4,5′, 8-trimethylpsoralen, 4′-(7-amino-2-aza-5-oxa)heptyl-4,5′,8-trimethylpsoralen, 4′-(-amino-2,6-diaza)nonyl-4,5′,8-trimethylpsoralen, 4′-(8-amino-5-aza-2-oxa)octyl-4,5′-(9-amino-5-aza-2-oxa)nonyl-4,5′, 8-trimethylpsoralen, 4′-(14-amino-2,6,11-triaza)te 4,5′,8-trimethylpsoralen, 5′-(4-amino-2-aza)butyl-4,4′,8-trimeth 2-aza)hexyl-4,4′,8-trimethylpsoralen and 5′-(4-amino-2-oxa)butyl-4,4′,8-trimethylpsoralen.38. A method according claim 35, wherein the biological composition comprises a blood product.39. A method according to claim 38, wherein the blood product consists essentially of plasma.40. A method according to claim 38, wherein the blood composition flows through the system as a result of a pressure differential which arises due to a hydrostatic head.41. A method according to claim 38, wherein the blood composition flows through the system as a result of a pressure differential which arises due to the use of a pump.42. A method according to claim 38, wherein the blood composition flows through the system at a flux between about 0.1 mL/cm2/min and about 10 mL/cm2/min.43. A method according to claim 42, wherein the blood composition flows through the system at a flux between about 0.2 mL/cm2/min and about 5 mL/cm2/min.44. A method according to claim 38, wherein the blood composition contains an original amount of factor XI, and said blood composition has at least about 91% of said original amount of factor XI after said treating with said system.45. A method according to claim 38 wherein said blood product additionally contains activated complement and said adsorbent particles additionally bind the activated complement in said blood product.
Varady Laszlo (Malden MA) Yang Yan B. (West Lafayette IN) Cook Steven E. (Wilmington DE) Regnier Fred E. (West Lafayette IN), Coated media for chromatography.
Groeger H. Gunter (Charlotte NC) Serad George A. (Charlotte NC) Felton Clinton D. (Charlotte NC), Fibrous structures containing immobilized particulate matter.
Groeger H. Gunter (Charlotte NC) Serad George A. (Charlotte NC) Felton Clinton D. (Charlotte NC), Fibrous structures containing particulate and including microfiber web.
Wollowitz Susan (Walnut Creek CA) Isaacs Stephen T. (Orinda CA) Rapoport Henry (Berkeley CA) Spielmann Hans P. (Lexington KY) Nerio Aileen (Santa Clara CA), Method for inactivating pathogens in blood using photoactivation of 4′-primary amino-substituted psoralens.
Wollowitz Susan ; Isaacs Stephen T. ; Rapoport Henry ; Spielmann Hans Peter ; Nerio Aileen, Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens.
Platz Matthew S. (Columbus OH) Goodrich ; Jr. Raymond P. (Pasadena CA) Yerram Nagendar (South Pasadena CA), Method of inactivation of viral and bacterial blood contaminants.
Pall David B. (Roslyn Estates NY) Harwood Colin F. (Glen Cove NY) Bradley Arthur (Floral Park NY) Brennan Timothy R. (Old Westbury NY), Method of making cylindrical fibrous filter structures.
Lin Lily (Berkeley CA) Corash Lawrence (Berkeley CA) Isaacs Stephen T. (Orinda CA) Hanson Carl V. (Berkeley CA) Cimino George D. (Richmond CA), Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen.
Markell Craig G. (White Bear Township ; Ramsey County MN) Hagen Donald F. (Woodbury MN) Hansen Paul E. (Lake Elmo MN) Baumann Nicholas R. (St. Paul MN), Particle-loaded nonwoven fibrous article for separations and purifications.
Berger Richard M. (Midlothian VA), Polyethylene terephthalate sheath/thermoplastic polymer core bicomponent fibers, method of making same and products form.
Wiesehahn Gary P. (Alameda CA) Creagan Richard P. (Alta Loma CA) Stevens David R. (Fremont CA) Giles Richard (Alameda CA), Preparation of inactivated viral vaccines.
Lee Eric Kin-Lam (Acton MA) Fouron Yves (Marlborough MA) Castino Franco (Sudbury MA) Zepp Charles Melvyn (Hardwick MA) Azad Abdul R. M. (Northborough MA), Process for simultaneously removing leukocytes and methylene blue from plasma.
Horowitz Bernard ; Valinsky Jay E. ; Geacintov Nicholas E. ; Williams Bolanle ; Rywkin Shanti B. ; Nunno Henrietta, Processes for photoreactive inactivation of a virus in blood cell or coagulation factor containing compositions and use thereof for preparing compositions useful for transfusion.
Boschetti Egisto (Croissy FRX) Girot Pierre (Paris FRX) Guerrier Luc P. (Chilly-Mazarin FRX), Removal of small exogenous molecules from biological fluids.
Buck Reinhold J. (Alleshausen DEX) Goehl Hermann J. (Bisingen-Zimmern DEX), Selectively permeable asymmetric membranes suitable for use in hemodialysis and processes for manufacturing such membran.
Degen Peter J. (Huntington NY) Gsell Thomas C. (Glen Cove NY), Self-supporting structures containing immobilized carbon particles and method for forming same.
Markell Craig G. (White Bear Township ; County of Ramsey MN) Hagen Donald F. (Woodbury MN) Luedtke James D. (St. Paul MN), Solid phase extraction medium.
Davankov Vadim A.,RUX ; Tsyurupa Maria P.,RUX ; Pavlova Ludmila A.,RUX ; Tur Dzidra R.,RUX, Sorbents for removing toxicants from blood or plasma, and method of producing the same.
Lin Lily (Berkeley CA) Corash Lawrence (Berkeley CA) Isaacs Stephen (Orinda CA) Cimino George (Richmond CA), Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsora.
Lin Lily (Berkeley CA) Corash Laurence (San Francisco CA), Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen.
Pall David B. (Roslyn Estates NY) Gsell Thomas C. (Glen Cove NY) Matkovich Vlado I. (Glen Cove NY) Bormann Thomas (Melville NY), System and method for processing biological fluid.
Kozlov, Mikhail; Moya, Wilson; Phillips, Michael W.; Ramaswamy, Senthilkumar; Gagnon, Brian, Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same.
Kozlov, Mikhail; Moya, Wilson; Phillips, Michael W.; Ramaswamy, Senthilkumar; Gagnon, Brian, Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same.
Kozlov, Mikhail; Moya, Wilson; Phillips, Michael W.; Ramaswamy, Senthilkumar; Gagnon, Brian, Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.